Page last updated: 2024-12-08
isoarecolone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 146970 |
CHEMBL ID | 265553 |
SCHEMBL ID | 1538433 |
MeSH ID | M0251449 |
Synonyms (18)
Synonym |
---|
AKOS005444150 |
1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)ethanone |
STK368575 |
isoarecolone |
CHEMBL265553 , |
1-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)ethanone |
ethanone, 1-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- |
100752-88-3 |
1-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)ethanone |
AB01332064-02 |
1-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)ethanone |
SCHEMBL1538433 |
1-(1,2,3,6-tetrahydro-1-methyl-4pyridinyl)ethanone |
YYJCSIKNHFNEQM-UHFFFAOYSA-N |
DTXSID70143498 |
NCGC00340368-01 |
bdbm50469743 |
ethanone, 1-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (9ci) |
Research Excerpts
Overview
Isoarecolone is a piperidine derivative with nicotine-like activity. It has a slightly different profile of behavioral actions in rodents.
Excerpt | Reference | Relevance |
---|---|---|
"Isoarecolone is a piperidine derivative with nicotine-like activity, but having a slightly different profile of behavioral actions in rodents." | ( Isoarecolone-induced enhancement of delayed matching to sample performance in monkeys: role of nicotinic receptors. Buccafusco, JJ; Gattu, M; Jackson, WJ; Terry, AV, 1995) | 2.46 |
Actions
Excerpt | Reference | Relevance |
---|---|---|
"Isoarecolone failed to inhibit the binding of the nicotinic ligand [125I]-alpha-bungarotoxin or of the muscarinic ligand [3H]-QNB." | ( Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Garcha, HS; Stolerman, IP; Whiteaker, P; Wonnacott, S, 1995) | 1.25 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (57.14) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |